TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05006677
Drug: vitamin K antagonists (VKAs)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collecting information of patients with VT who received VKAs
Study: NCT05716854
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD).
Study: NCT05006677
Drug: antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collecting information of patients with VT who received antiplatelet agents
Study: NCT00002004
Drug: CD4 Antigens
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05640245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized treatment; parallel-group
Study: NCT04742660
Drug: Ammonium Glycyrrhizinate
Normalized name: AMMONIUM GLYCYRRHIZINATE TRIHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
Study: NCT05400395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral intake(BID) for 24 weeks
Study: NCT05674877
Drug: Opioid-based group (OB) (placebo/saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the opioid-based group will receive placebo boluses and infusions of saline.
Study: NCT05674877
Drug: Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine.
Study: NCT05278338
Drug: JMT103
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Study: NCT05278338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Study: NCT06505551
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for 3 consecutive days
Study: NCT04683939
Drug: BNT141
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT05709444
Drug: RAAS inhibition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
Study: NCT04936698
Drug: PTU 50 MG Oral Tablet
Normalized name: PTU 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: to treat if the patient has hyperthyroidism
Study: NCT05716984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
Study: NCT06598371
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06598371
Drug: KSQ-004EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT04327661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06381154
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06381154
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06381154
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo intratumoral photoradiation
Study: NCT01874314
Drug: SQ109
Normalized name: SQ109
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg or 450mg of SQ109 administered orally, once daily for 7 days.
Study: NCT04466215
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six placebo tablets taken orally once daily for two weeks
Study: NCT03164447
Drug: Optimized background therapy (OBT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
Study: NCT06487598
Drug: inj insulin to one group
Normalized name: Gel-One Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group- only inj insulin for 3 months.
Study: NCT06487598
Drug: Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
Study: NCT06625073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
Study: NCT06626113
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid
Study: NCT06155383
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, Bid orally, D1-14, every 3 weeks
Study: NCT04737109
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT per institutional standards
Study: NCT05384665
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
Study: NCT05384665
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
Study: NCT05384665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
Study: NCT05646394
Drug: Vitamin K antagonist standard intensity
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
Study: NCT05646394
Drug: Vitamin K antagonist high intensity
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
Study: NCT05328817
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
Study: NCT05483894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
Study: NCT06620523
Drug: CoQ10 1200 mg orally with Glutathione 1000 mg orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
Study: NCT06620523
Drug: Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
Study: NCT04916119
Drug: IBI323
Approvals — FDA: no, EMA: no, PMDA: no
Description: In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
Study: NCT05905068
Drug: RN0191 INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sterile solution in each bottle for subcutaneous (SC) injection
Study: NCT06139419
Drug: induction chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
Study: NCT05044325
Drug: GSK3884464
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3884464 will be administered
Study: NCT05044325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GSK3884464 will be administered.
Study: NCT04789174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05008393
Drug: PJS-539 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PJS-539 dose 1 daily for 10 days.
Study: NCT05008393
Drug: PJS-539 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PJS-539 Dose 2 daily for 10 days.
Study: NCT05008393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo daily for 10 days.
Study: NCT06391593
Drug: ALTO-203 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active, ALTO-203 25 μg
Study: NCT05596006
Drug: ASIMOMMY®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASIMOMMY 500 mg
Study: NCT05596006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of placebo 500mg.
Study: NCT06391593
Drug: ALTO-203 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active, ALTO-203 75 μg
Study: NCT06391593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator, Placebo-to-match
Study: NCT05043701
Drug: Personalized drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: A personalized drug combination will be prescribed to each patient based on the functional drug screen
Study: NCT05600062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT05209841
Drug: Low dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
Study: NCT05209841
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheters will be sealed with 3mL of 0.9% sodium chloride
Study: NCT04436458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
Study: NCT04860960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5N saline provided every 2 weeks intravenously
Study: NCT05823467
Drug: TMP-SMX DS
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Antibiotic - used to treat post operative wound infections.
Study: NCT04984278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oromucosal spray
Study: NCT06215755
Drug: VRG50635
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks.
Study: NCT04518306
Drug: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04518306
Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04518306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03390530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05326763
Drug: Dextrose 50%
Normalized name: DEXTROSE 50% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
Study: NCT05448547
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
Study: NCT05333276
Drug: TQB3602 Capsule + AK105 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
Study: NCT06431438
Drug: TQA3810
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Study: NCT05388058
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically
Study: NCT05787613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05900089
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
Study: NCT05528913
Drug: Fasenra Prefilled Syringe
Normalized name: Fasenra Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasenra 60mg s.c. administration at weeks 0,4 and 8
Study: NCT05900336
Drug: Sodium Naproxen
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
Study: NCT05900336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
Study: NCT05405894
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-yearly infusion of zoledronic acid following denosumab discontinuation
Study: NCT04768842
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05405660
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration
Study: NCT06193148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo orally for single dose
Study: NCT06242418
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
Study: NCT06242418
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
Study: NCT05180175
Drug: Top down treatment if patient at high risk
Normalized name: Kool-Down Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
Study: NCT04891497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 240mg orally twice daily for 3 consecutive days
Study: NCT05585125
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol
Study: NCT05228834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Study: NCT05548491
Drug: AZR-MD-001 ointment/semi-solid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: ointment/semi-solid drug
Study: NCT05346848
Drug: Association of ADT and EBRT
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD
Study: NCT04512365
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule that contains only dextrose filler administered during the first or second laboratory visit.
Study: NCT05055934
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05525234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
Study: NCT05090904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06730802
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
Study: NCT06730802
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will receive standard statin therapy.
Study: NCT04405180
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
Study: NCT05935306
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
Study: NCT04734275
Drug: AZD5718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
Study: NCT05320133
Drug: JWC containing quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
Study: NCT05320133
Drug: Bismuth-containing quadruple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
Study: NCT05672212
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil
Study: NCT05646758
Drug: TQB2934 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
Study: NCT05852197
Drug: anticoagulant or antiplatelet drugs
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of anticoagulant or antiplatelet drugs
Study: NCT05467670
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
Study: NCT05114499
Drug: GV-971
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV-971 450mg bid
Study: NCT05988710
Drug: Buccal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for buccal administration
Study: NCT05988710
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral administration
Study: NCT06027307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
Study: NCT05941741
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles